• VolitionRx outlined clinical evidence supporting its Nu.Q NETs assay for sepsis management, positioning Nu.Q H3.1 as a potential differentiator for diagnosis, severity assessment, and prognosis.
• Results have already been generated across multiple international studies, with most of the supporting papers now peer reviewed and published.
• The update framed the test as a simple, low-cost approach for conditions linked to NETosis, where elevated levels are associated with organ failure and death.
• Management cited active discussions with large diagnostic companies to accelerate development, targeting an estimated $3.8 billion annual total addressable market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN14796) on July 30, 2026, and is solely responsible for the information contained therein.